Pacira Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pacira Biosciences Inc 's ROA in the second quarter of 2026?
Pacira Biosciences inc achieved a return on average assets (ROA) of 1.17 % in its second quarter of 2026, this is above PCRX's average return on assets of -5.83%.
Pacira Biosciences Inc assets over the 12 months ending in its second quarter of 2026 are valued at $1,256 million

ROA has improved compared to 0.39% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 199 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 2462, from total ROA ranking in the first quarter of 2026 at 2780.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-18.52 %	-23.83 %	-18.58 %	-14.73 %	-6.65 %
Y / Y Net Income Change	-	-39.4 %	-89.79 %	-	-
Net Income (TTM) in million	15	5	7	21	-127
Return On Assets (TTM)	1.17 %	0.39 %	0.49 %	1.44 %	-8.22 %
PCRX's Total Ranking	# 2462	# 2780	# 2002	# 3203	# 3174
Total Assets (TTM) in million	1,253	1,209	1,265	1,298	1,537
Seq. Total Assets Change	3.64 %	-4.46 %	-2.52 %	-15.59 %	-3.11 %
Seq. Net Income Change	59.57 %	78.13 %	-69.86 %	-	-

PCRX's 5 Years Annual ROA >> Back to PCRX Management Effectiveness >> Compare PCRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 68
Sector	# 200
Overall	# 2113

Return On Assets Statistics
High	Average	Low
13.92 %	-5.83 %	-45.52 %
(Dec 31 2020)		(Jun 30 2013)

Financial Statements
Pacira Biosciences Inc 's Assets	$ 1,253 million	PCRX's Balance sheet
Pacira Biosciences Inc 's Income	$ 5 million	Quarterly PCRX's Income Statement
PCRX's Income by Division		See PCRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-18.58 %	-12.07 %	4.99 %	-18.91 %	56.67 %
Total Assets in million	1,265	1,554	1,767	1,683	2,075
Y / Y Net Income Change	-	-	163.72 %	-62.1 %	-71.15 %
Net Income in million	7	-100	42	16	42
Annual Return On Assets	0.56 %	-6.41 %	2.37 %	0.95 %	2.02 %

PCRX's 5 Years Annual ROA >> Back to PCRX Management Effectiveness >> Compare PCRX ROA to its Competitors

Comment on PCRX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 0.56 % compared to prior year, due to annual net income growth of % to $7.03 million, and due to decline of value in Pacira Biosciences Inc 's assets by -18.58 % to $1,264.92 million, compared to $1,264.92 a year before.

More Return On Assets Ratios
PCRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PCRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PCRX's Competitors
Subscribers only: Roa for Pacira Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for PCRX's Customers

You may also want to know
PCRX's Roi	PCRX's Inventory Turnover Ratio	PCRX's Growth Rates	PCRX's Dividend Comparisons
	PCRX's Profitability Ratios	PCRX's Asset Turnover Ratio	PCRX's Dividend Growth
PCRX's Roe	PCRX's Valuation Ratios	PCRX's Financial Strength Ratios	PCRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Community Health Systems Inc	3.17 %
Vaso Corporation	2.92 %
Collegium Pharmaceutical Inc	2.72 %
National Vision Holdings Inc	2.53 %
Conmed Corporation	2.44 %
Merck and Co Inc	2.42 %
Privia Health Group Inc	2.41 %
Lifestance Health Group Inc	2.33 %
Bio rad Laboratories Inc	2.21 %
Pfizer Inc	2.12 %
Mimedx Group Inc	1.99 %
Revvity Inc	1.97 %
Alkermes Plc	1.96 %
Becton Dickinson And Company	1.77 %
Teva Pharmaceutical Industries Limited	1.77 %
Immucell Corporation	1.76 %
Envista Holdings Corporation	1.69 %
Atricure Inc	1.62 %
Black Hawk Acquisition Corporation	1.56 %
Repligen Corp	1.41 %
Omada Health Inc	1.41 %
Arvinas Inc	1.29 %
Pacira Biosciences inc	1.17 %
Waters Corporation	1.12 %
Cormedix Inc	1.11 %
Warby Parker Inc	1.05 %
Surgery Partners Inc	1.02 %
Staar Surgical Co	0.84 %
Biomarin Pharmaceutical Inc	0.82 %
Icu Medical Inc	0.75 %

Date modified: 2026-08-31T11:29:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.